Promising drug may help kids with rare kidney disorder avoid dialysis
NCT ID NCT05001269
First seen Oct 31, 2025 · Last updated May 02, 2026 · Updated 22 times
Summary
This study tested a drug called nedosiran in 27 children from birth to 11 years old who have primary hyperoxaluria, a rare condition that causes harmful oxalate buildup and can lead to kidney failure. The goal was to see if the drug safely lowers oxalate levels in the urine, which could help control the disease. The treatment is not a cure, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HYPEROXALURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Rochester, Minnesota, 55905, United States
-
Clinical Research Site
Hamilton, Ontario, L8S 4K1, Canada
-
Clinical Research Site
Heidelberg, 69120, Germany
-
Clinical Research Site
Fukuoka, 830-0011, Japan
-
Clinical Research Site
Nagoya, 467-8602, Japan
-
Clinical Research Site
Beirut, 1100, Lebanon
-
Clinical Research Site
Bialystok, 15-274, Poland
-
Clinical Research Site
Barcelona, 08035, Spain
-
Clinical Research Site
Yenimahalle, Ankara, 06506, Turkey (Türkiye)
-
Clinical Trial Site
Bonn, 53127, Germany
-
Clinical Trial Site
Roma, 00165, Italy
-
Clinical Trial Site
Dubai, +971, United Arab Emirates
-
Clinical Trial Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.